Monitor for further dilution risk as the company's cash runway is short (approx. 1-2 quarters at current burn rate) despite the recent $2.5M offering. The Phase 2/3 trial initiation is a positive catalyst, but the financial fragility and going-concern warning dominate near-term risk. Watch for additional financing announcements or partnership deals.
Price Chart
Executive Summary
Silexion Therapeutics reported Q2 2026 financial results, highlighting the transition of its lead candidate SIL204 into an active Phase 2/3 clinical program for locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026. The company also closed a $2.5M public offering post-quarter to support clinical execution and Nasdaq compliance. However, the net loss widened to $3.6M from $2.5M YoY, and cash burn continues with only $2.2M in cash as of June 30, 2026, raising going-concern risk.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was approximately $3.6M, up 44% from $2.5M in Q2 2025.
- Cash and cash equivalents fell to $2.2M as of June 30, 2026, from $6.0M at December 31, 2025.
- Phase 2/3 trial of SIL204 initiated at Tel Aviv Sourasky Medical Center on July 29, 2026.
- Closed a public offering on August 13, 2026, with gross proceeds of approximately $2.5M and net proceeds of approximately $2.1M.
- Company estimates shareholders' equity at approximately $3.2M, exceeding Nasdaq's $2.5M minimum requirement.
- R&D expenses for Q2 2026 were $2.2M, up 120% YoY, driven by clinical trial preparations.
- The company disclosed substantial doubt about its ability to continue as a going concern in its forward-looking statements.
Financial Impact
Net loss widened by $1.1M YoY to $3.6M; cash burn rate of ~$1.8M per quarter based on cash decline from $6.0M to $2.2M over 6 months.
Risk Factors
- Going-concern risk: substantial doubt about ability to continue as a going concern explicitly noted.
- Dilution risk: recent public offering and ongoing at-the-market sales will dilute existing shareholders.
- Clinical risk: Phase 2/3 trial may fail to meet endpoints, wiping out equity value.
- Nasdaq delisting risk: despite current compliance, low market cap ($1M) and potential bid price issues remain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-004136 |
| Document: zk2635972.htm | 0001178913-26-004136 |
| Document: 0001178913-26-004136-index-headers.html | 0001178913-26-004136 |
| Document: 0001178913-26-004136-index.html | 0001178913-26-004136 |
| Document: 0001178913-26-004136.txt | 0001178913-26-004136 |
| 8-K Data (Synthetic) | 0001178913-26-004136 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1657 (−7.74%) |
Oct 5, 2026 22d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1657 (+36.95%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1657 (−40.18%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1657 (+40.25%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 $0.1650 | ▲ +48.11% | ▲ +48.77% | $0.1657 (+47.89%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 $0.1657 | ▲ +47.96% | ▲ +48.67% | $0.1657 (+47.96%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1657 (+33.29%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1657 (+60.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers